Dr. Naggie is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
2100 Erwin Rd
Durham, NC 27705Phone+1 919-684-8111
Education & Training
- Duke University HospitalFellowship, Infectious Disease, 2007 - 2009
- Duke University HospitalResidency, Internal Medicine, 2002 - 2005
- Johns Hopkins University School of MedicineClass of 2002
Certifications & Licensure
- NC State Medical License 2002 - 2025
- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Infectious Disease
Clinical Trials
- Sofosbuvir-Containing Regimens Without Interferon For Treatment of Acute Hepatitis C Virus (HCV) Infection Start of enrollment: 2014 May 30
- Glecaprevir/Pibrentasvir Fixed-dose Combination Treatment for Acute Hepatitis C Virus Infection Start of enrollment: 2019 Nov 15
Publications & Presentations
PubMed
- Electronic Clinical Decision Support Tools: Strategies to Improve the Management of Lower Respiratory Tract Infections in Low-Resource Settings.L Gayani Tillekeratne, Warsha De Soyza, Maria D Iglesias-Ussel, Stefany Olague, Dhammika Palangasinghe
The American Journal of Tropical Medicine and Hygiene. 2024-12-04 - Prevalence of and Risk Factors for Liver Enzyme Elevation After Hepatitis C Virologic Cure.Helen L Zhang, Hayley Nemeth, E Wilbur Woodhouse, Clemontina A Davenport, Cliburn Chan
Journal of Viral Hepatitis. 2024-12-01 - 2 citationsMASLD in people with HIV exhibits higher fibrosis stage despite lower disease activity than in matched controls.Daniela S Allende, Oscar Cummings, Alice L Sternberg, Cynthia A Behling, Danielle Carpenter
Alimentary Pharmacology & Therapeutics. 2024-11-01
Press Mentions
- Asthma Drug Did Not Reduce Symptom Duration in Mild to Moderate COVIDOctober 22nd, 2024
- Time to Sustained Recovery Among Outpatients with COVID-19 Receiving Montelukast vs PlaceboOctober 18th, 2024
- Higher Dose of Ivermectin, and for Longer, Still No Help Against COVIDFebruary 23rd, 2023
- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: